EpiCept has announced the proposed public offering of up to 10 million shares of its common stock, par value $0.0001 per share, and warrants to purchase up to 10 million shares of its common stock.
Subscribe to our email newsletter
EpiCept intends to use the net proceeds it receives to meet its working capital needs and general corporate purposes through July 2008 and to pay certain fees owed to Hercules Technology Growth Capital.
Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group, acted as the exclusive placement agent for the offering.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.